`HbA1c` PROJECT - NOVO NORDISK FARMASHORT PUBLICATION

Abstract

Type 2 diabetes is a progressive disease in which insulin secretion diminishes continuously in time. There is a strong correlation between glycaemic burden and late complications in type 1 and type 2 diabetes2,3.
In order to avoid these complications, ADA currently recommends HbA1c levels of < 7.0% and the IDF6 and AACE7 recommend a target of ≤ 6.5%8-10.
Glycaemic control can be achieved initially by diet and exercise habits and/or the prescription of ≥1 OAD. Exogenous insulin therapy is required in addition to or as an alternative to OAD therapy as type 2 diabetes progresses.
Insulin therapy is often delayed due to concerns about injection, hypoglycaemia, and weight gain13-14. Insulin analogues, due its properties may improve patients adherence to initiating insulin therapy in an earlier stage of the disease.
Novo Nordisk initiated and conducted in May 2007 the `HbA1c` Project in 13 diabetes centres in Romania.
The HbA1c measurements in 9.000 type 2 diabetic patients diagnosed for 6-8 years on OADs and/or human insulin treatment showed that only 19% were < 7% and 81% were ≥ 7%.

ADA - American Diabetes Association; IDF - International Diabetes Federation AACE - American Association of Clinical Endocrinologists OAD - oral antidiabetic drug